BRPI0918142A2 - composição farmaclógica tópica, seu método de preparação, bem como uso da forma de ácido livre de ácido 2-(4-isobutifilfenil)prpiônico - Google Patents

composição farmaclógica tópica, seu método de preparação, bem como uso da forma de ácido livre de ácido 2-(4-isobutifilfenil)prpiônico

Info

Publication number
BRPI0918142A2
BRPI0918142A2 BRPI0918142A BRPI0918142A BRPI0918142A2 BR PI0918142 A2 BRPI0918142 A2 BR PI0918142A2 BR PI0918142 A BRPI0918142 A BR PI0918142A BR PI0918142 A BRPI0918142 A BR PI0918142A BR PI0918142 A2 BRPI0918142 A2 BR PI0918142A2
Authority
BR
Brazil
Prior art keywords
isobutyphylphenyl
preparation
well
propionic acid
free form
Prior art date
Application number
BRPI0918142A
Other languages
English (en)
Inventor
Diane L Kozwich
Kanu Patel
Stephen G Carter
Zhen Zhu
Original Assignee
Biochemics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biochemics Inc filed Critical Biochemics Inc
Publication of BRPI0918142A2 publication Critical patent/BRPI0918142A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
BRPI0918142A 2008-09-10 2009-09-10 composição farmaclógica tópica, seu método de preparação, bem como uso da forma de ácido livre de ácido 2-(4-isobutifilfenil)prpiônico BRPI0918142A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9567208P 2008-09-10 2008-09-10
PCT/US2009/056568 WO2010030821A2 (en) 2008-09-10 2009-09-10 Ibuprofen for topical administration

Publications (1)

Publication Number Publication Date
BRPI0918142A2 true BRPI0918142A2 (pt) 2015-12-01

Family

ID=41447140

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0918142A BRPI0918142A2 (pt) 2008-09-10 2009-09-10 composição farmaclógica tópica, seu método de preparação, bem como uso da forma de ácido livre de ácido 2-(4-isobutifilfenil)prpiônico

Country Status (6)

Country Link
US (4) US20100137443A1 (pt)
EP (2) EP3574921A1 (pt)
AU (1) AU2009291755B2 (pt)
BR (1) BRPI0918142A2 (pt)
CA (2) CA2726726A1 (pt)
WO (1) WO2010030821A2 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100137443A1 (en) 2008-09-10 2010-06-03 Biochemics, Inc. Ibuprofen for Topical Administration
MX349176B (es) 2008-09-22 2017-07-14 Biochemics Inc Suministro transdermico de farmaco empleando un osmolito y un agente vasoactivo.
CA2784827C (en) * 2009-12-16 2018-10-23 Shasun Pharmaceuticals Limited Composition of dexibuprofen transdermal hydrogel
CN102854263B (zh) * 2012-08-31 2014-04-16 石家庄中硕药业集团有限公司 一种同时测定布洛芬注射液中布洛芬及精氨酸含量的方法
US11007161B1 (en) * 2014-12-31 2021-05-18 Eric Morrison Ibuprofen nanoparticle carriers encapsulated with hermatic surfactant films
US10596117B1 (en) 2014-12-31 2020-03-24 Eric Morrison Lipoleosomes as carriers for aromatic amide anesthetic compounds
US10561627B2 (en) 2014-12-31 2020-02-18 Eric Morrison Ibuprofen nanoparticle carriers encapsulated with hermetic surfactant films
WO2016137411A1 (en) 2015-02-25 2016-09-01 Pharmactive İlaç Sanayi Ve Ticaret A. Ş. Topical spray composition comprising ibuprofen and lidocaine
GB2546513B (en) * 2016-01-20 2020-09-16 Cubic Pharmaceuticals Ltd Process of preparing active pharmaceutical ingredient salts
CA3063870A1 (en) 2017-05-15 2018-11-22 Biochemics, Inc. Transdermally-delivered combination drug therapy for pain
BR112020006577A2 (pt) 2017-10-06 2020-10-06 Cargill, Incorporated solução aquosa de glicosídeo de esteviol, composição de bebida, adoçante, e, edulcorante
WO2020069013A1 (en) 2018-09-27 2020-04-02 BioPhysics Pharma, Inc. Transdermal drug delivery system
US11504327B1 (en) 2019-01-21 2022-11-22 Eric Morrison Method of preparing nanoparticles by hot-melt extrusion
CA3135584A1 (en) 2019-04-06 2020-10-15 Cargill, Incorporated Methods for making botanical extract composition

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4185100A (en) * 1976-05-13 1980-01-22 Johnson & Johnson Topical anti-inflammatory drug therapy
DE3013839A1 (de) 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
US4440777A (en) 1981-07-07 1984-04-03 Merck & Co., Inc. Use of eucalyptol for enhancing skin permeation of bio-affecting agents
US4933184A (en) 1983-12-22 1990-06-12 American Home Products Corp. (Del) Menthol enhancement of transdermal drug delivery
US4826689A (en) 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
US4663364A (en) 1984-09-05 1987-05-05 Kao Corporation Biocidal fine powder, its manufacturing method and a suspension for agricultural use containing the above powder
US4859704A (en) 1987-10-15 1989-08-22 Oratech Pharmaceutical Development Corporation Water soluble ibuprofen compositions and methods of making them
GB8905815D0 (en) * 1989-03-14 1989-04-26 Beecham Group Plc Medicament
WO1991008733A1 (en) 1989-12-20 1991-06-27 Schering Corporation Stable cream and lotion bases for lipophilic drug compositions
US5093133A (en) * 1990-01-24 1992-03-03 Mcneil-Ppc, Inc. Method for percutaneous delivery of ibuprofen using hydroalcoholic gel
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5210099A (en) 1991-02-11 1993-05-11 American Home Products Corporation Analgesic compositions
EP0584108B1 (en) 1991-05-13 2000-08-16 The Boots Company PLC Pharmaceutical composition comprising ibuprofen salt
US5229130A (en) 1991-12-20 1993-07-20 Cygnus Therapeutics Systems Vegetable oil-based skin permeation enhancer compositions, and associated methods and systems
US5645854A (en) 1993-06-23 1997-07-08 Masiz; John J. Molecular transdermal transport system
US5460821A (en) 1993-06-23 1995-10-24 Masiz; John J. Molecular transdermal transport system
US5853751A (en) 1993-06-23 1998-12-29 Masiz; John J. Molecular transdermal transport system
IT1265001B1 (it) 1993-12-16 1996-10-17 Zambon Spa Composizione farmaceutica per uso topico contenente acido (s)-2-(4- isobutilfenil) propionico
DE19509807A1 (de) 1995-03-21 1996-09-26 Basf Ag Verfahren zur Herstellung von Wirkstoffzubereitungen in Form einer festen Lösung des Wirkstoffs in einer Polymermatrix sowie mit diesem Verfahren hergestellte Wirkstoffzubereitungen
US5654337A (en) 1995-03-24 1997-08-05 II William Scott Snyder Topical formulation for local delivery of a pharmaceutically active agent
FR2732221B1 (fr) 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue
FR2741262B1 (fr) 1995-11-20 1999-03-05 Oreal Utilisation d'un antagoniste de tnf-alpha pour le traitement des rougeurs cutanees d'origine neurogene
US5976566A (en) 1997-08-29 1999-11-02 Macrochem Corporation Non-steroidal antiinflammtory drug formulations for topical application to the skin
US5895658A (en) 1997-09-17 1999-04-20 Fossel; Eric T. Topical delivery of L-arginine to cause tissue warming
US5922332A (en) 1997-09-17 1999-07-13 Fossel; Eric T. Topical delivery of arginine to overcome pain
US6207713B1 (en) 1997-09-17 2001-03-27 Eric T. Fossel Topical and oral delivery of arginine to cause beneficial effects
US6306130B1 (en) 1998-04-07 2001-10-23 The General Hospital Corporation Apparatus and methods for removing blood vessels
US6368618B1 (en) 1999-07-01 2002-04-09 The University Of Georgia Research Foundation, Inc. Composition and method for enhanced transdermal absorption of nonsteroidal anti-inflammatory drugs
US7105172B1 (en) 1999-11-18 2006-09-12 Bolla John D Treatment of rosacea
US6645520B2 (en) * 1999-12-16 2003-11-11 Dermatrends, Inc. Transdermal administration of nonsteroidal anti-inflammatory drugs using hydroxide-releasing agents as permeation enhancers
DE10001546A1 (de) 2000-01-14 2001-07-19 Beiersdorf Ag Verfahren zur kontinuierlichen Herstellung und Beschichtung von Selbstlebemassen auf Basis von Polyisobutylen mit mindestens einem pharmazeutischen Wirkstoff
FR2808191B1 (fr) 2000-04-28 2004-03-05 Oreal Extrait de vegetal de l'espece olea europaea comme inhibiteur de no-synthase et utilisations
US6635274B1 (en) 2000-10-27 2003-10-21 Biochemics, Inc. Solution-based transdermal drug delivery system
CN1655762B (zh) * 2002-06-17 2010-05-26 塔罗制药美国公司 布洛芬混悬剂
US20070292461A1 (en) * 2003-08-04 2007-12-20 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US6927206B2 (en) 2003-06-06 2005-08-09 Procyte Corporation Compositions and methods for treatment of rosacea
EP1588697A1 (en) * 2004-04-16 2005-10-26 Kurt H. Prof. Dr. Bauer Emulsion gel for topical application of pharmaceuticals
CA2563678A1 (en) 2004-04-19 2005-11-03 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
US20050256204A1 (en) 2004-05-11 2005-11-17 Bitter Patrick H Sr Topical phenyl-epinephrine Rosacea treatment
US7433356B2 (en) * 2004-05-13 2008-10-07 International Business Machines Corporation Methods and apparatus for creating addresses
US20060013866A1 (en) * 2004-07-16 2006-01-19 Carter Stephen G Transdermal drug delivery formulations with optimal amounts of vasodilators therein
US7288263B2 (en) 2004-09-13 2007-10-30 Evera Laboratories, Llc Compositions and methods for treatment of skin discoloration
DE102005000755A1 (de) * 2005-01-04 2006-07-20 Continental Aktiengesellschaft Fahrzeugluftreifen
US20060217690A1 (en) 2005-03-22 2006-09-28 Bastin Norman J Method for treating various dermatological and muscular conditions using electromagnetic radiation
WO2007103555A2 (en) 2006-03-08 2007-09-13 Nuviance, Inc. Transdermal drug delivery compositions and topical compositions for application on the skin
RU2009117468A (ru) * 2006-10-12 2010-11-20 Рото Фармасьютикал Ко., Лтд. (Jp) Наружный препарат для кожи
US8354116B2 (en) 2007-06-18 2013-01-15 Biochemics, Inc. Bifunctional synthetic molecules
US20100137443A1 (en) 2008-09-10 2010-06-03 Biochemics, Inc. Ibuprofen for Topical Administration

Also Published As

Publication number Publication date
CA2749941C (en) 2018-04-24
US20100137443A1 (en) 2010-06-03
AU2009291755B2 (en) 2016-04-21
US20120329875A1 (en) 2012-12-27
US20170095433A1 (en) 2017-04-06
EP3574921A1 (en) 2019-12-04
CA2726726A1 (en) 2010-03-18
US20200009095A1 (en) 2020-01-09
EP2373346A2 (en) 2011-10-12
CA2749941A1 (en) 2010-03-18
WO2010030821A3 (en) 2011-01-20
AU2009291755A1 (en) 2010-03-18
EP2373346B1 (en) 2019-06-12
US9561174B2 (en) 2017-02-07
WO2010030821A2 (en) 2010-03-18

Similar Documents

Publication Publication Date Title
BRPI0918142A2 (pt) composição farmaclógica tópica, seu método de preparação, bem como uso da forma de ácido livre de ácido 2-(4-isobutifilfenil)prpiônico
BRPI0919447A2 (pt) derivados do ácido 1-amino-2-ciclobutiletilborônico
BRPI0919738A2 (pt) 3h-imidazo[4,5-c] piridino-6-carboxamidas como agentes anti-inflamatórios
BRPI1009118A2 (pt) 3h-imidazo[4,5-c] piridina-6-carboxamidas como agentes anti-inflamatórios
BRPI1009281A2 (pt) composição oftálmica tópica
BRPI0911594A2 (pt) di-hidropirazolonas substistuídas, seu processo de preparação e seu uso, bem como medicamentos
BRPI0916973A2 (pt) anticorpos para ccr2
BRPI0919090A2 (pt) prepraração de ácido acético.
BRPI0919155A2 (pt) composição aquosa injetável
BRPI0908303A2 (pt) Recuperação de ácidos orgânicos
BRPI0911782A2 (pt) composição de insulina de ação super rápida
BRPI0814065A2 (pt) Derivados de alcoóis de 1-fenil-2-piridinil alquila como inibidores da fosfodiesterase
BRPI0911126A2 (pt) Formulação aquosa estável contendo esporo
BRPI0914544A2 (pt) derivados de pirimidona substituídos
IT1393045B1 (it) Composizioni contenenti monogliceridi di acidi organici da c1 a c7 e glicerolo, loro preparazione ed uso come antibatterici in zootecnia.
BRPI0913833A2 (pt) uso de corantes ácidos
BRPI0920540A2 (pt) método de produção de álcool
BRPI0823256A2 (pt) Uso de sacarose como substrato para produção fermentativa de 1,2-propanodiol
BRPI0914301A2 (pt) derivados de pirimidin-4-ona substituída
BRPI1015102A2 (pt) Método para induzir formação de etanol.
BRPI0908412A2 (pt) método para purificar álcool de fermentação
BRPI0923481A2 (pt) laminado para vidro laminado
BR112013010169A8 (pt) uso de monascus na produção de ácido orgânico.
BRPI0913267A2 (pt) uso do ácido succínico
BR112012004300A2 (pt) preparação de ácido acético.

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2383 DE 06-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.